Who is suitable for the treatment of Enantuzumab?

Elranatamab is a bispecific antibody used to treat multiple myeloma (MM), especially in relapsed or refractory patients who have failed multiple front-line therapies. According to the current internationally approved indications, eractuzumab is suitable for adults with multiple myeloma who have received at least four front-line treatment options, including proteasome inhibitors (such as bortezomib), immunomodulators (such as lenalidomide), and anti-CD38 monoclonal antibodies (such as daratumumab), for individuals whose disease cannot be controlled.

These patients have often experienced complex pathological stages such as disease recurrence, efficacy exhaustion, and drug tolerance, and have limited response to traditional treatments. Enactuzumab As a BCMA/CD3-targeted dual-antibody drug, Enactuzumab can still induce the immune system to re-recognize and kill cancer cells in people with high tumor burden, rapid disease progression, and poor prognosis, thereby achieving disease control and even deep remission.

In addition, for patients who are not qualified to receiveCAR-T therapy, such as those who are unable to receive cell therapy due to old age, poor physical fitness, complex underlying diseases, etc.,enatuzumab as a "ready-to-use" targeted drug, is a more practical and low-threshold option. Its subcutaneous delivery also makes it more accessible in the outpatient setting, avoiding the time and cost burden of hospitalization.

Although ernatumumab is mainly targeted at patients with highly refractory myeloma, as its research continues to deepen, its indications may be expanded in the early treatment stage in the future, especially for people with clear expression of BCMA, which will have clearer benefit expectations. With the popularity of biomarker testing in the treatment of hematological tumors, eractuzumab is expected to serve as an important part of precision immunotherapy and bring long-term benefits to patients with specific genetic backgrounds.

Reference materials:https://www.drugs.com/mtm/elranatamab.html